BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35502835)

  • 21. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
    La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
    Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of FOXO1 fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded specimens in the diagnosis of alveolar rhabdomyosarcoma.
    Downs-Kelly E; Shehata BM; López-Terrada D; Weaver J; Patel RM; Hartke M; Tubbs RR; Skacel M; Goldblum JR
    Diagn Mol Pathol; 2009 Sep; 18(3):138-43. PubMed ID: 19704258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs.
    Manceau L; Richard Albert J; Lollini PL; Greenberg MVC; Gilardi-Hebenstreit P; Ribes V
    PLoS Genet; 2022 May; 18(5):e1009782. PubMed ID: 35604932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH
    Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
    Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
    Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
    Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
    Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
    Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.
    Yuan H; Qin F; Movassagh M; Park H; Golden W; Xie Z; Zhang P; Sklar J; Li H
    Cancer Discov; 2013 Dec; 3(12):1394-403. PubMed ID: 24089019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of FOXO1 break-apart status by fluorescence in situ hybridization in atypical alveolar rhabdomyosarcoma.
    Fu L; Jin Y; Jia C; Zhang J; Tai J; Li H; Chen F; Shi J; Guo Y; Ni X; He L
    Sci China Life Sci; 2017 Jul; 60(7):721-728. PubMed ID: 28646473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.
    Olanich ME; Barr FG
    Expert Opin Ther Targets; 2013 May; 17(5):607-23. PubMed ID: 23432728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis.
    Lynn M; Shah N; Conroy J; Ennis S; Morris T; Betts D; O'Sullivan M
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):213-21. PubMed ID: 24614150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
    Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapy.
    Stegmaier S; Bielack SS; Leuschner I; Klingebiel T; Koscielniak E
    J Clin Oncol; 2012 Nov; 30(32):4039-40; author reply 4040-1. PubMed ID: 23032620
    [No Abstract]   [Full Text] [Related]  

  • 34. The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.
    Thway K; Wang J; Wren D; Dainton M; Gonzalez D; Swansbury J; Fisher C
    Virchows Arch; 2015 Aug; 467(2):217-24. PubMed ID: 25912319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adult Primary Pineal Alveolar Rhabdomyosarcoma with FOXO1 Gene Rearrangement and OLIG2 Expression: A Rare Case Report and Literature Review.
    Xie L; Wang W; Zhou H; Han Z; Xu J; Xu Z; Xiang J
    Int J Surg Pathol; 2022 Oct; 30(7):769-775. PubMed ID: 35188829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
    Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
    Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.
    Herrero Martín D; Boro A; Schäfer BW
    PLoS One; 2013; 8(1):e55072. PubMed ID: 23372815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma.
    de Traux De Wardin H; Cyrta J; Dermawan JK; Guillemot D; Orbach D; Aerts I; Pierron G; Antonescu CR
    Genes Chromosomes Cancer; 2024 Apr; 63(4):e23232. PubMed ID: 38607246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.